Longitudinal Regional Flortaucipir Profiles in Preclinical Alzheimer’s Disease: Evaluation using A4 phase 3 trial with Solanezumab

Documenti analoghi

• Longitudinal Regional Flortaucipir Profiles in Preclinical Alzheimer’s Disease: Evaluation using A4 phase 3 trial with Solanezumab
  di: Vikas Kotari, et al.
  Pubblicazione: (2024)
• Flortaucipir patterns in preclinical Alzheimer’s disease: an evaluation of TRAILBLAZER‐ALZ 3 baseline data
  di: Vikas Kotari, et al.
  Pubblicazione: (2025)
• Repeat Testing Reliability of Plasma pTau217 in Preclinical AD
  di: Robert A. Rissman, et al.
  Pubblicazione: (2024)
• Estimating Preclinical Alzheimer's Disease Populations by p ‐tau217 in the United States, Japan, Germany, and China
  di: Zachary Sheff, et al.
  Pubblicazione: (2025)
• Quantitative‐ and visual read‐based flortaucipir PET T+ criteria for the pathophysiological assessment of Alzheimer’s Disease
  di: Ilke Tunali, et al.
  Pubblicazione: (2024)